《大行》中金升亞盛醫藥(06855.HK)目標價至69元 APG-2575數據亮眼
中金發表研究報告指,亞盛醫藥-B(06855.HK)近日在美國臨床腫瘤學會(ASCO)年會上口頭報告了Bcl-2
抑制劑APG-2575(lisaftoclax)合併阿扎胞(甘)針對髓系惡性腫瘤的Ib/II期研究數據,並更新了MDM2-p53抑制劑APG-115(alrizomadlin)治療晚期腺樣囊性癌(ACC)或其它實體瘤患者的II期臨床研究資料。
該行認為,APG-2575 R/R AML數據亮眼,展現出克服維奈克拉抗藥性的潛力。鑑於維奈克拉尚未核准1L MDS,此適應症競爭格局良好,建議關注臨床開展情況。
該行基本維持集團今明兩年的淨虧損預測,分別為10.95億及3.19億元人民幣,維持「跑贏行業」評級,目標價上調25.5%至69元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.